[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia]. [electronic resource]
Producer: 20200227Description: 113-128 p. digitalISSN:- 1769-6917
- Antineoplastic Agents -- therapeutic use
- Catalytic Domain
- Clinical Decision-Making
- DNA Mutational Analysis -- methods
- DNA, Neoplasm -- analysis
- Drug Resistance, Neoplasm -- genetics
- Drug Substitution
- Fusion Proteins, bcr-abl -- antagonists & inhibitors
- High-Throughput Nucleotide Sequencing
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Molecular Biology
- Mutation, Missense
- Point Mutation
- Protein Domains
- Protein Kinase Inhibitors -- therapeutic use
- Role
No physical items for this record
Publication Type: Consensus Development Conference; Journal Article; Practice Guideline; Review
There are no comments on this title.
Log in to your account to post a comment.